{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:26:21Z","timestamp":1792106781001,"version":"4.4.0"},"reference-count":110,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Multiple myeloma is an incurable plasma B-cell malignancy with 5-year survival rates approximately 10-30% lower than other hematologic cancers. Treatment options include combination chemotherapy followed by autologous stem cell transplantation. However, not all patients are eligible for autologous stem cell transplantation, and current pharmacological agents are limited in their ability to reduce tumor burden and extend multiple myeloma remission times. The \u201cchemokine network\u201d is comprised of chemokines and their cognate receptors, and is a critical component of the normal bone microenvironment as well as the tumor microenvironment of multiple myeloma. Antagonists targeting chemokine-receptor 1 (CCR1) may provide a novel approach for treating multiple myeloma. <jats:italic>In vitro<\/jats:italic><jats:bold\/> CCR1 antagonists display a high degree of specificity, and in some cases signaling bias. <jats:italic>In vivo<\/jats:italic><jats:bold\/> studies have shown they can reduce tumor burden, minimize osteolytic bone damage, deter metastasis, and limit disease progression in multiple myeloma models. While multiple CCR1 antagonists have entered the drug pipeline, none have entered clinical trials for treatment of multiple myeloma. This review will discuss whether current CCR1 antagonists are a viable treatment option for multiple myeloma, and studies aimed at identifying which CCR1 antagonist(s) are most appropriate for this disease.<\/jats:p>","DOI":"10.3389\/fendo.2022.846310","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T18:58:19Z","timestamp":1648580299000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma"],"prefix":"10.3389","volume":"13","author":[{"given":"Annette","family":"Gilchrist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Echeverria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple Myeloma Epidemiology and Survival: A Unique Malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"B2","unstructured":"U.S. Cancer Statistics Data Visualizations Tool, Based on November 2018 Submission Data (1999-2016)2019"},{"key":"B3","article-title":"Cancer Stat Facts: Myeloma","year":"2021","journal-title":"Cancer Stat"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1179\/1024533214Z.000000000333","article-title":"Multiple Myeloma","volume":"20","author":"Mehta","year":"2015","journal-title":"Hematology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/medsci9010003","article-title":"Epidemiology, Staging, and Management of Multiple Myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting Racial Disparities in Multiple Myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1038\/s41467-018-04989-w","article-title":"Identification of Multiple Risk Loci and Regulatory Mechanisms Influencing Susceptibility to Multiple Myeloma","volume":"9","author":"Went","year":"2018","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41375-019-0703-6","article-title":"Genetic Predisposition for Multiple Myeloma","volume":"34","author":"Pertesi","year":"2020","journal-title":"Leukemia"},{"key":"B10","article-title":"Multiple Myeloma: Diagnosis and Treatment","volume":"95","author":"Michels","year":"2017","journal-title":"Am Fam Physician"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0866","article-title":"New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma","volume":"22","author":"Landgren","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for Multiple Myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313","article-title":"Continued Improvement in Survival in Multiple Myeloma: Changes in Early Mortality and Outcomes in Older Patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2017.1.498","article-title":"Management of Multiple Myeloma in the Newly Diagnosed Patient","volume":"2017","author":"Mateos","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B16","doi-asserted-by":"publisher","first-page":"101150","DOI":"10.1016\/j.beha.2020.101150","article-title":"The Changing Role of High Dose Melphalan With Stem Cell Rescue in the Treatment of Newly Diagnosed Multiple Myeloma in the Era of Modern Therapies-Back to the Future","volume":"33","author":"Kazandjian","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1804356","article-title":"Immunomodulatory Drug- and Proteasome Inhibitor-Backbone Regimens in the Treatment of Relapsed Multiple Myeloma: An Evidence-Based Review","volume":"13","author":"Sanchez","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab Plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2017-0328","article-title":"EMA Review of Daratumumab for the Treatment of Adult Patients With Multiple Myeloma","volume":"23","author":"Tzogani","year":"2018","journal-title":"Oncologist"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, Lenalidomide, and Dexamethasone With or Without Elotuzumab in Patients With Untreated, High-Risk Multiple Myeloma (SWOG-1211): Primary Analysis of a Randomised, Phase 2 Trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0778","article-title":"3rd, Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) for the Management of Relapsed Multiple Myeloma","volume":"17","author":"Banerjee","year":"2021","journal-title":"Future Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25584","article-title":"Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma","volume":"117","author":"Niesvizky","year":"2011","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-021-00407-5","article-title":"Phase 1 Open-Label Study of Panobinostat, Lenalidomide, Bortezomib\u2009+\u2009Dexamethasone in Relapsed and Relapsed\/Refractory Multiple Myeloma","volume":"11","author":"Laubach","year":"2021","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3324\/haematol.2015.129189","article-title":"Treatment of Relapsed and Refractory Multiple Myeloma","volume":"101","author":"Sonneveld","year":"2016","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12018-015-9184-y","article-title":"Chemokines and Bone","volume":"13","author":"Gilchrist","year":"2015","journal-title":"Clin Rev Bone Miner Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/164_2020_349","article-title":"Chemokines and Bone","volume":"262","author":"Gilchrist","year":"2020","journal-title":"Handb Exp Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum Levels of Macrophage Inflammatory Protein-1 Alpha (MIP-1alpha) Correlate With the Extent of Bone Disease and Survival in Patients With Multiple Myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200113116","article-title":"Antisense Inhibition of Macrophage Inflammatory Protein 1-Alpha Blocks Bone Destruction in a Model of Myeloma Bone Disease","volume":"108","author":"Choi","year":"2001","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2004.11.015","article-title":"MIP-1alpha Utilizes Both CCR1 and CCR5 to Induce Osteoclast Formation and Increase Adhesion of Myeloma Cells to Marrow Stromal Cells","volume":"33","author":"Oba","year":"2005","journal-title":"Exp Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384784","article-title":"CCR1 Blockade Reduces Tumor Burden and Osteolysis In Vivo in a Mouse Model of Myeloma Bone Disease","volume":"120","author":"Dairaghi","year":"2012","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-093294","article-title":"MLN3897, a Novel CCR1 Inhibitor, Impairs Osteoclastogenesis and Inhibits the Interaction of Multiple Myeloma Cells and Osteoclasts","volume":"110","author":"Vallet","year":"2007","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.253526","article-title":"Expression of the Chemokine Receptor CCR1 Promotes the Dissemination of Multiple Myeloma Plasma Cells In Vivo","volume":"106","author":"Zeissig","year":"2021","journal-title":"Haematologica"},{"key":"B34","unstructured":"LaubachJP\n          Multiple Myeloma: Clinical Features, Laboratory Manifestations, and Diagnosis2021"},{"key":"B35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/nyas.13038","article-title":"Multiple Myeloma in the Marrow: Pathogenesis and Treatments","volume":"1364","author":"Fairfield","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25391","article-title":"Rapid Assessment of Hyperdiploidy in Plasma Cell Disorders Using a Novel Multi-Parametric Flow Cytometry Method","volume":"94","author":"Sidana","year":"2019","journal-title":"Am J Hematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1177\/1947601910392989","article-title":"Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point From a Nutrient-Sensing Cell Growth Checkpoint(s)","volume":"1","author":"Foster","year":"2010","journal-title":"Genes Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26161","article-title":"Current Approaches to Management of High-Risk Multiple Myeloma","volume":"96","author":"Goldman-Mazur","year":"2021","journal-title":"Am J Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-017-0397-5","article-title":"Myeloma and Bone Disease","volume":"15","author":"Panaroni","year":"2017","journal-title":"Curr Osteoporos Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7261","article-title":"The Impact of the Bone Marrow Microenvironment on Multiple Myeloma (Review)","volume":"42","author":"Hou","year":"2019","journal-title":"Oncol Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/B978-0-12-386469-7.00002-5","article-title":"The Microenvironment and Molecular Biology of the Multiple Myeloma Tumor","volume":"110","author":"Lemaire","year":"2011","journal-title":"Adv Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12233","article-title":"Targeting the Bone Marrow Microenvironment in Multiple Myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple Myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5025","article-title":"Notch Signaling Deregulation in Multiple Myeloma: A Rational Molecular Target","volume":"6","author":"Colombo","year":"2015","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.3390\/cancers12123643","article-title":"Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma","volume":"12","author":"Zeissig","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2018.10.004","article-title":"Metastatic Bone Disease: Pathogenesis and Therapeutic Options: Up-Date on Bone Metastasis Management","volume":"15","author":"D'Oronzo","year":"2019","journal-title":"J Bone Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1182\/blood.V128.22.484.484","article-title":"Osteocyte Apoptosis Attracts Myeloma Cells to Bone and Supports Progression Through Regulation of the Bone Marrow Microenvironment","volume":"128","author":"Trotter","year":"2016","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.01063","article-title":"The Role of Tumor Microenvironment in Genomic Instability of Malignant Tumors","volume":"10","author":"Sonug\u00fcr","year":"2019","journal-title":"Front Genet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041200","article-title":"Metabolic Features of Multiple Myeloma","volume":"19","author":"El Arfani","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3400","article-title":"Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma","volume":"75","author":"Maiso","year":"2015","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-690743","article-title":"Dependence on Glutamine Uptake and Glutamine Addiction Characterize Myeloma Cells: A New Attractive Target","volume":"128","author":"Bolzoni","year":"2016","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.06.010","article-title":"Adipocytes Contribute to the Growth and Progression of Multiple Myeloma: Unraveling Obesity Related Differences in Adipocyte Signaling","volume":"380","author":"Bullwinkle","year":"2016","journal-title":"Cancer Lett"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6020","article-title":"Mature Adipocytes in Bone Marrow Protect Myeloma Cells Against Chemotherapy Through Autophagy Activation","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013832","article-title":"Multiple Myeloma Cells Induce Lipolysis in Adipocytes and Uptake Fatty Acids Through Fatty Acid Transporter Proteins","volume":"139","author":"Panaroni","year":"2021","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s12032-014-0953-0","article-title":"Circulating Levels of Soluble Fas Ligand Reflect Disease Progression in Multiple Myeloma","volume":"31","author":"Alexandrakis","year":"2014","journal-title":"Med Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3676","article-title":"Accessory Cells of the Microenvironment Protect Multiple Myeloma From T-Cell Cytotoxicity Through Cell Adhesion-Mediated Immune Resistance","volume":"19","author":"de Haart","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.5.1658.405a19_1658_1667","article-title":"Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple Myeloma: Available Therapies and Causes of Drug Resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2016.0470","article-title":"The Diagnosis and Treatment of Multiple Myeloma","volume":"113","author":"Gerecke","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"B61","article-title":"Multiple Myeloma: From Diagnosis to Treatment","volume":"42","author":"Eslick","year":"2013","journal-title":"Aust Fam Physician"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138","article-title":"Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14466","article-title":"A Guide to Chemokines and Their Receptors","volume":"285","author":"Hughes","year":"2018","journal-title":"FEBS J"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2021.08.001","article-title":"Anticancer Opportunities at Every Stage of Chemokine Function","volume":"42","author":"Ortiz Zacar\u00edas","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00277","article-title":"Biased and G Protein-Independent Signaling of Chemokine Receptors","volume":"5","author":"Steen","year":"2014","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 Protein-Serine\/Threonine Kinases in Human Cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharmacol Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/ijms18020342","article-title":"Mechanisms of Regulation of the Chemokine-Receptor Network","volume":"18","author":"Stone","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00483","article-title":"Targeting Chemokine-Glycosaminoglycan Interactions to Inhibit Inflammation","volume":"11","author":"Crijns","year":"2020","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.06.017","article-title":"Chemokines in Multiple Myeloma","volume":"34","author":"Aggarwal","year":"2006","journal-title":"Exp Hematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4523","article-title":"Chemokines CCL2, 3, 14 Stimulate Macrophage Bone Marrow Homing, Proliferation, and Polarization in Multiple Myeloma","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1320","article-title":"Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment","volume":"75","author":"Ponzetta","year":"2015","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0115","article-title":"HIF-2\u03b1 Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12\/CXCR4 and CCR1","volume":"77","author":"Vandyke","year":"2017","journal-title":"Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01178-9","article-title":"EMTome: A Resource for Pan-Cancer Analysis of Epithelial-Mesenchymal Transition Genes and Signatures","volume":"124","author":"Vasaikar","year":"2021","journal-title":"Br J Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25627","article-title":"Phase I\/II Trial of the CXCR4 Inhibitor Plerixafor in Combination With Bortezomib as a Chemosensitization Strategy in Relapsed\/Refractory Multiple Myeloma","volume":"94","author":"Ghobrial","year":"2019","journal-title":"Am J Hematol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/17425255.2020.1711884","article-title":"Clinical Significance of Chemokine Receptor Antagonists","volume":"16","author":"Miao","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12835","article-title":"Identifying Bias in CCR1 Antagonists Using Radiolabelled Binding, Receptor Internalization, \u03b2-Arrestin Translocation and Chemotaxis Assays","volume":"171","author":"Gilchrist","year":"2014","journal-title":"Br J Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.11.144","article-title":"Therapeutic Potential of CCR1 Antagonists for Multiple Myeloma","volume":"3","author":"Karash","year":"2011","journal-title":"Future Med Chem"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.2174\/1568026614666140827144440","article-title":"Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance","volume":"14","author":"Karash","year":"2014","journal-title":"Curr Top Med Chem"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2003131","DOI":"10.1136\/jitc-2021-003131","article-title":"CCR1 and CCR5 Mediate Cancer-Induced Myelopoiesis and Differentiation of Myeloid Cells in the Tumor","volume":"10","author":"Zilio","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2174\/156802610791561237","article-title":"CCR1 Antagonists: What Have We Learned From Clinical Trials","volume":"10","author":"Gladue","year":"2010","journal-title":"Curr Top Med Chem"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.099424","article-title":"Deficiency of Chemokine Receptor CCR1 Causes Osteopenia Due to Impaired Functions of Osteoclasts and Osteoblasts","volume":"285","author":"Hoshino","year":"2010","journal-title":"J Biol Chem"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2011.586634","article-title":"CCR1 as a Target for Multiple Myeloma","volume":"15","author":"Vallet","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.671","article-title":"Macrophage Inflammatory Protein 1-Alpha Is a Potential Osteoclast Stimulatory Factor in Multiple Myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.130","article-title":"Increased Expression of Macrophage Inflammatory Protein-1alpha on Trephine Biopsies Correlates With Extensive Bone Disease, Increased Angiogenesis and Advanced Stage in Newly Diagnosed Patients With Multiple Myeloma","volume":"23","author":"Roussou","year":"2009","journal-title":"Leukemia"},{"key":"B85","article-title":"Clinical Significance of Chemokine Receptor (CCR1, CCR2 and CXCR4) Expression in Human Myeloma Cells: The Association With Disease Activity and Survival","volume":"91","author":"Vande Broek","year":"2006","journal-title":"Haematologica"},{"key":"B86","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10585-006-9038-6","article-title":"Role of CCR1 and CCR5 in Homing and Growth of Multiple Myeloma and in the Development of Osteolytic Lesions: A Study in the 5TMM Model","volume":"23","author":"Menu","year":"2006","journal-title":"Clin Exp Metastasis"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.04.010","article-title":"Tolerability and Efficacy of Inhaled AZD4818, a CCR1 Antagonist, in Moderate to Severe COPD Patients","volume":"104","author":"Kerstjens","year":"2010","journal-title":"Respir Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/annrheumdis-2014-eular.2352","article-title":"Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of BI 638683, A Novel CCR1 Antagonist","volume":"73","author":"Baum","year":"2014","journal-title":"Ann Rheumatol Dis"},{"key":"B89","unstructured":"Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects2011"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02365-16","article-title":"Pharmacological Blockade of the Chemokine Receptor CCR1 Protects Mice From Systemic Candidiasis of Hematogenous Origin","volume":"61","author":"Lionakis","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1002372107","article-title":"Inactivation of Chemokine (C-C Motif) Receptor 1 (CCR1) Suppresses Colon Cancer Liver Metastasis by Blocking Accumulation of Immature Myeloid Cells in a Mouse Model","volume":"107","author":"Kitamura","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1021\/jm5003167","article-title":"Discovery of the CCR1 Antagonist, BMS-817399, for the Treatment of Rheumatoid Arthritis","volume":"57","author":"Santella","year":"2014","journal-title":"J Med Chem"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-eular.3871","article-title":"THU0109 Lack of Efficacy of CCR1 Antagonist BMS-817399 in Patients With Moderate to Severe Rheumatoid Arthritis: Results of 12-Week Proof-Of-Concept Study","volume":"73","author":"Kivitz","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509358188","article-title":"No Significant Effect of Orally Administered Chemokine Receptor 1 Antagonist on Intercellular Adhesion Molecule-3 Expression in Relapsing\u2013Remitting Multiple Sclerosis Patients","volume":"16","author":"Reuss","year":"2010","journal-title":"Mult Scler"},{"key":"B95","article-title":"DSE Regulates the Malignant Characters of Hepatocellular Carcinoma Cells by Modulating CCL5\/CCR1 Axis","volume":"9","author":"Liao","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13487","article-title":"C-C Chemokine Receptor Type 1 Mediates Osteopontin-Promoted Metastasis in Hepatocellular Carcinoma","volume":"109","author":"Zhu","year":"2018","journal-title":"Cancer Sci"},{"key":"B97","doi-asserted-by":"publisher","first-page":"20508","DOI":"10.1038\/s41598-020-77450-y","article-title":"Multiple Myeloma Hinders Erythropoiesis and Causes Anaemia Owing to High Levels of CCL3 in the Bone Marrow Microenvironment","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0896(02)00559-X","article-title":"Structure-Activity Relationships of Xanthene Carboxamides, Novel CCR1 Receptor Antagonists","volume":"11","author":"Naya","year":"2003","journal-title":"Bioorg Med Chem"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201605","article-title":"Chemokine Receptor CCR1 Antagonist CCX354-C Treatment for Rheumatoid Arthritis: CARAT-2, a Randomised, Placebo Controlled Clinical Trial","volume":"72","author":"Tak","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B100","first-page":"227","article-title":"Combination Therapy of Chemokine Receptor Inhibition Plus PDL-1 Blockade Potentiates Anti-tumor Effects in a Murine Model of Breast Cancer","volume-title":"J Immunother Cancer","author":"Jung","year":"2015"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.5.3141","article-title":"The Human Specific CCR1 Antagonist CP-481,715 Inhibits Cell Infiltration and Inflammatory Responses in Human CCR1 Transgenic Mice","volume":"176","author":"Gladue","year":"2006","journal-title":"J Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2008.01365.x","article-title":"Evaluation of the Effect of the Specific CCR1 Antagonist CP-481715 on the Clinical and Cellular Responses Observed Following Epicutaneous Nickel Challenge in Human Subjects","volume":"59","author":"Borregaard","year":"2008","journal-title":"Contact Dermatitis"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1002\/art.24978","article-title":"MLN3897 Plus Methotrexate in Patients With Rheumatoid Arthritis: Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of an Oral CCR1 Antagonist in a Phase IIa, Double-Blind, Placebo-Controlled, Randomized, Proof-of-Concept Study","volume":"60","author":"Vergunst","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1021\/jm801416q","article-title":"Novel Pyrrolidine Ureas as C-C Chemokine Receptor 1 (CCR1) Antagonists","volume":"52","author":"Merritt","year":"2009","journal-title":"J Med Chem"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2010.07.082","article-title":"Novel Pyrrolidine Heterocycles as CCR1 Antagonists","volume":"20","author":"Merritt","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.757559","article-title":"Partial Agonist and Biased Signaling Properties of the Synthetic Enantiomers J113863\/UCB35625 at Chemokine Receptors CCR2 and CCR5","volume":"292","author":"Corbisier","year":"2017","journal-title":"J Biol Chem"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706912","article-title":"Pharmacological Blockade of CCR1 Ameliorates Murine Arthritis and Alters Cytokine Networks In Vivo","volume":"149","author":"Amat","year":"2006","journal-title":"Br J Pharmacol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M908864199","article-title":"A Small Molecule Antagonist of Chemokine Receptors CCR1 and CCR3. Potent Inhibition of Eosinophil Function and CCR3-Mediated HIV-1 Entry","volume":"275","author":"Sabroe","year":"2000","journal-title":"J Biol Chem"},{"key":"B109","first-page":"A369","article-title":"Inhibition Of Chemokine Receptors CCR1 and CCR6 As Promising Therapies For Autoimmune Diseases Such As Rheumatoid Arthritis and Psoriasi","volume-title":"Ann Rheum Dis","author":"Dairaghi","year":"2013"},{"key":"B110","doi-asserted-by":"crossref","DOI":"10.1039\/9781849735346-00329","article-title":"CHAPTER 11 Ccr1","volume-title":"Anti-Inflammatory Drug Discovery","author":"Robert Merritt","year":"2012"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.846310\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T18:58:30Z","timestamp":1648580310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.846310\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":110,"alternative-id":["10.3389\/fendo.2022.846310"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.846310","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"article-number":"846310"}}